SIETES :: 93212 citas

Resultados de la búsqueda por CERIVASTATINA REFINAR BÚSQUEDA

1.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

2.

Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]

3.

Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]

4.

Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]

5.

Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]

6.

Garattini S, Bertele V. Rosiglitazone and the need for a new drug safety agency. BMJ 2010;341:781-2. [Ref.ID 89479]

7.

McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010;13:11-37. [Ref.ID 88544]

8.

Abecia Inchaurregui LC, Abasolo Osinaga E, Etxeandia Ikobaltzeta I, Burgos Alonso N, López Picado A, Fernández Bilbao M. Evolución de la utilización de hipolipemiantes en la comunidad autónoma del País Vasco (1992-2005). Aten Farmaceutica 2009;11:361-7. [Ref.ID 87455]

9.

García del Pozo J, Madurga M, de Abajo FJ. Utilización de hipolipemiantes en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86460]

10.

Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109. [Ref.ID 84984]

11.

Klotz U. Drug-related risks. Eur J Clin Pharmacol 2007;63:983-4. [Ref.ID 81426]

12.

Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]

13.

Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature 2007;446:26 de abril. [Ref.ID 80079]

14.

Anónimo. Neuropathies périphériques et statines. Prescrire 2007;27:269-70. [Ref.ID 79734]

15.

McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-43. [Ref.ID 79332]

16.

Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B, Meneghelli I, Venegoni M, Cutroneo PM, Vaccheri A, Velo G, Montanaro N. Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol 2007;63:73-9. [Ref.ID 79050]

17.

Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11. [Ref.ID 78930]

18.

Anónimo. Fewer than 30 Lipobay cases can still be settled, Bayer claims. Scrip 2006;3215:14. [Ref.ID 78651]

19.

Avorn J. Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med 2006;355:2169-71. [Ref.ID 78556]

20.

Clarke A, Deeks JJ, Shakir SAW. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006;29:175-81. [Ref.ID 77468]